3 research outputs found
ICO-ICS Praxi per al tractament mèdic i amb irradiació de cà ncer gà stric i d'unió esofagogà strica
Tractament mèdic; Tractament amb irradiaciĂł; CĂ ncer de la uniĂł esofagogĂ stricaTratamiento mĂ©dico; Tratamiento con irradiaciĂłn; Cáncer de la uniĂłn esofagogástricaMedical treatment; Irradiation treatment; Esophagogastric union cancerEl cĂ ncer gĂ stric (CG) Ă©s actualment el vuitè tipus de cĂ ncer mĂ©s prevalent a la UniĂł Europea on, segons les estimacions, el 2018 es calculen 80.211 casos diagnosticats en ambdĂłs sexes amb una taxa estimada d'incidència estandarditzada per edat de 6,4 casos per cada 100.000 habitants. En el cas d'Espanya, segons dades d'incidència i mortalitat del projecte GLOBOCAN i de l'Observatori Europeu del CĂ ncer, se situa en novè lloc, desprĂ©s del cĂ ncer de bufeta i el cĂ ncer uterĂ, pel que fa a freqüència. Els objectius d'aquesta guia sĂłn: Desenvolupar, difondre, implementar i avaluar resultats de l'ICO-ICSPraxi de cĂ ncer gĂ stric i d'uniĂł esofagogĂ strica. Disminuir la variabilitat terapèutica entre els pacients tractats als diferents centres d'aquesta instituciĂł. Implementar els resultats de la terapèutica en els pacients amb cĂ ncer gĂ stric i d'uniĂł esofagogĂ strica tractats d'acord amb les recomanacions d'aquesta guia.El cáncer gástrico (CG) es actualmente el octavo tipo de cáncer más prevalente en la UniĂłn Europea donde, segĂşn las estimaciones, el 2018 se calculan 80.211 casos diagnosticados en ambos sexos con una tasa estimada de incidencia estandarizada por edad de 6,4 casos por cada 100.000 habitantes. En el caso de España, segĂşn datos de incidencia y mortalidad del proyecto GLOBOCAN y del Observatorio Europeo del Cáncer, se sitĂşa en noveno lugar, despuĂ©s del cáncer de vejiga y el cáncer uterino, en cuanto a frecuencia. Los objetivos de esta guĂa son: Desarrollar, difundir, implementar y evaluar resultados del ICO-ICSPraxi de cáncer gástrico y de uniĂłn esofagogástrica. Disminuir la variabilidad terapĂ©utica entre los pacientes tratados en los diferentes centros de esta instituciĂłn. Implementar los resultados de la terapĂ©utica en los pacientes con cáncer gástrico y de uniĂłn esofagogástrica tratados de acuerdo con las recomendaciones de esta guĂa.Gastric cancer (GC) is currently the eighth most prevalent type of cancer in the European Union where, according to estimates, 80,211 cases diagnosed in both sexes are estimated at an estimated rate of incidence standardized by age of 6.4 cases per 100,000 people. In the case of Spain, according to the incidence and mortality data of the GLOBOCAN project and the European Cancer Observatory, it is placed ninth, after bladder cancer and uterine cancer, as it happens frequently. The objectives of this guide are: Developing, disseminating, implementing and evaluating the results of the ICO-ICSPraxi of gastric cancer and esophagogastric binding. Decrease the therapeutic variability between patients treated at the different centers of this institution. Implement the results of therapeutic treatment in patients with gastric cancer and esphagogastric binding treated in accordance with the recommendations of this guide
Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
CDK inhibitors; Breast cancer; PalbociclibInhibidors de CDK; Cà ncer de mama; PalbociclibInhibidores de CDK; Cáncer de mama; PalbociclibDrug-drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the 'First Workshop on Pharmacology and Management of CDK4/6 Inhibitors: Consensus about Concomitant Medications'. The article is structured into two modules. The educational module includes background information regarding drug metabolism, corrected QT (QTc) interval abnormalities, management of psychotropic drugs and a comprehensive review of selected adverse effects of palbociclib and ribociclib. The collaborative module presents the conclusions of the five working groups, each of which comprised five experts from different fields. From these conclusions positive lists of drugs for treating common comorbid conditions that can be safely administered concomitantly with palbociclib and/or ribociclib were developed
Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
CDK inhibitors; Breast cancer; PalbociclibInhibidors de CDK; Cà ncer de mama; PalbociclibInhibidores de CDK; Cáncer de mama; PalbociclibDrug-drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the 'First Workshop on Pharmacology and Management of CDK4/6 Inhibitors: Consensus about Concomitant Medications'. The article is structured into two modules. The educational module includes background information regarding drug metabolism, corrected QT (QTc) interval abnormalities, management of psychotropic drugs and a comprehensive review of selected adverse effects of palbociclib and ribociclib. The collaborative module presents the conclusions of the five working groups, each of which comprised five experts from different fields. From these conclusions positive lists of drugs for treating common comorbid conditions that can be safely administered concomitantly with palbociclib and/or ribociclib were developed